Evaluating the Use of microRNA Blood Tests for Gastric Cancer Screening in a Stratified Population-Level Screening Program: An Early Model-Based Cost-Effectiveness Analysis
Affiliations
- PMID: 32940235
- DOI: 10.1016/j.jval.2020.04.1829
Abstract
Objectives: To evaluate cost-effectiveness of a novel screening strategy using a microRNA (miRNA) blood test as a screen, followed by endoscopy for diagnosis confirmation in a 3-yearly population screening program for gastric cancer.
Methods: A Markov cohort model has been developed in Microsoft Excel 2016 for the population identified to be at intermediate risk (Singaporean men, aged 50-75 years with Chinese ethnicity). The interventions compared were (1) initial screening using miRNA test followed by endoscopy for test-positive individuals and a 3-yearly follow-up screening for test-negative individuals (proposed strategy), and (2) no screening with gastric cancer being diagnosed clinically (current practice). The model was evaluated for 25 years with a healthcare perspective and accounted for test characteristics, compliance, disease progression, cancer recurrence, costs, utilities, and mortality. The outcomes measured included incremental cost-effectiveness ratios, cancer stage at diagnosis, and thresholds for significant variables.
Results: The miRNA-based screening was found to be cost-effective with an incremental cost-effectiveness ratio of $40 971/quality-adjusted life-year. Key drivers included test costs, test accuracy, cancer incidence, and recurrence risk. Threshold analysis highlights the need for high accuracy of miRNA tests (threshold sensitivity: 68%; threshold specificity: 77%). A perfect compliance to screening would double the cancer diagnosis in early stages compared to the current practice. Probabilistic sensitivity analysis reported the miRNA-based screening to be cost-effective in >95% of iterations for a willingness to pay of $70 000/quality-adjusted life-year (approximately equivalent to 1 gross domestic product/capita) CONCLUSIONS: The miRNA-based screening intervention was found to be cost-effective and is expected to contribute immensely in early diagnosis of cancer by improving screening compliance.
Keywords: cost-effectiveness of miRNA test; gastric cancer screening; miRNA cancer screening; miRNA test; model-based cost-effectiveness.
Copyright © 2020 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.
Similar articles
- Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.Health Technol Assess. 2006 Mar;10(8):1-142, iii-iv. doi: 10.3310/hta10080.PMID: 16545207 Review.
- A cost-effectiveness analysis evaluating endoscopic surveillance for gastric cancer for populations with low to intermediate risk.PLoS One. 2013 Dec 27;8(12):e83959. doi: 10.1371/journal.pone.0083959. eCollection 2013.PMID: 24386314 Free PMC article.
- Cost-Effectiveness of DNA Stool Testing to Screen for Colorectal Cancer [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2007 Dec 20.PMID: 25879132 Free Books & Documents. Review.
- A Markov Analysis of Screening for Late-Onset Cytomegalovirus Disease in Cytomegalovirus High-Risk Kidney Transplant Recipients.Clin J Am Soc Nephrol. 2018 Feb 7;13(2):290-298. doi: 10.2215/CJN.05080517. Epub 2017 Oct 12.PMID: 29025787 Free PMC article.
- Digital Breast Tomosynthesis with Hologic 3D Mammography Selenia Dimensions System for Use in Breast Cancer Screening: A Single Technology Assessment [Internet].Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2017 Sep 4. Report from the Norwegian Institute of Public Health No. 2017-08.PMID: 29553669 Free Books & Documents. Review.
No hay comentarios:
Publicar un comentario